The HSP co-inducer BGP-15 can prevent the metabolic side effects of the atypical antipsychotics

Zsuzsanna Literáti-Nagy, K. Tory, Botond Literáti-Nagy, Attila Kolonics, Z. Török, I. Gombos, G. Balogh, László Vígh, I. Horváth, J. Mandl, B. Sümegi, Philip L. Hooper, L. Vígh

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Weight gain and dysfunction of glucose and lipid metabolism are well-known side effects of atypical antipsychotic drugs (AAPD). Here, we address the questionwhether a heat-shock protein (HSP) co-inducer, insulin sensitizer drug candidate, BGP-15, can prevent AAPD-induced glucose, lipid, and weight changes. We also examined how an AAPD alters HSP expression and whether BGP-15 alters that expression. Four different experiments are reported on the AAPD BGP-15 interventions in a human trial of healthy men, a rodent animal model, and an in vitro adipocyte cell culture system. Olanzapine caused rapid insulin resistance in healthy volunteers and was associated with decreased level of HSP72 in peripheral mononuclear blood cells. Both changes were restored by the administration of BGP-15. In Wistar rats, weight gain and insulin resistance induced by clozapine were abolished by BGP-15. In 3T3L1 adipocytes, clozapine increased intracellular fat accumulation, and BGP-15 inhibited this process. Taken together, our results indicate that BGP-15 inhibits multiple metabolic side effects of atypical antipsychotics, and this effect is likely to be related to its HSP co-inducing ability.

Original languageEnglish
Pages (from-to)517-521
Number of pages5
JournalCell Stress and Chaperones
Volume17
Issue number4
DOIs
Publication statusPublished - Jul 2012

Fingerprint

Heat-Shock Proteins
Antipsychotic Agents
Clozapine
Insulin
olanzapine
Adipocytes
Weight Gain
Insulin Resistance
Glucose
BGP 15
Lipid Metabolism
Cell culture
Wistar Rats
Rats
Rodentia
Blood Cells
Healthy Volunteers
Animals
Blood
Animal Models

Keywords

  • Atypical antipsychotic drugs
  • BGP-15
  • Diabetes
  • Heat-shock proteins
  • HSP
  • HSP inducers
  • HSP72
  • Hydroxylamines
  • Insulin resistance
  • Insulin signaling
  • Membranes
  • Metabolic syndrome
  • Mitochondria
  • Schizophrenia
  • Side effects
  • Therapy
  • Weight gain

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology

Cite this

The HSP co-inducer BGP-15 can prevent the metabolic side effects of the atypical antipsychotics. / Literáti-Nagy, Zsuzsanna; Tory, K.; Literáti-Nagy, Botond; Kolonics, Attila; Török, Z.; Gombos, I.; Balogh, G.; Vígh, László; Horváth, I.; Mandl, J.; Sümegi, B.; Hooper, Philip L.; Vígh, L.

In: Cell Stress and Chaperones, Vol. 17, No. 4, 07.2012, p. 517-521.

Research output: Contribution to journalArticle

Literáti-Nagy, Zsuzsanna ; Tory, K. ; Literáti-Nagy, Botond ; Kolonics, Attila ; Török, Z. ; Gombos, I. ; Balogh, G. ; Vígh, László ; Horváth, I. ; Mandl, J. ; Sümegi, B. ; Hooper, Philip L. ; Vígh, L. / The HSP co-inducer BGP-15 can prevent the metabolic side effects of the atypical antipsychotics. In: Cell Stress and Chaperones. 2012 ; Vol. 17, No. 4. pp. 517-521.
@article{62e124be7614468e85f446e1360b0c1c,
title = "The HSP co-inducer BGP-15 can prevent the metabolic side effects of the atypical antipsychotics",
abstract = "Weight gain and dysfunction of glucose and lipid metabolism are well-known side effects of atypical antipsychotic drugs (AAPD). Here, we address the questionwhether a heat-shock protein (HSP) co-inducer, insulin sensitizer drug candidate, BGP-15, can prevent AAPD-induced glucose, lipid, and weight changes. We also examined how an AAPD alters HSP expression and whether BGP-15 alters that expression. Four different experiments are reported on the AAPD BGP-15 interventions in a human trial of healthy men, a rodent animal model, and an in vitro adipocyte cell culture system. Olanzapine caused rapid insulin resistance in healthy volunteers and was associated with decreased level of HSP72 in peripheral mononuclear blood cells. Both changes were restored by the administration of BGP-15. In Wistar rats, weight gain and insulin resistance induced by clozapine were abolished by BGP-15. In 3T3L1 adipocytes, clozapine increased intracellular fat accumulation, and BGP-15 inhibited this process. Taken together, our results indicate that BGP-15 inhibits multiple metabolic side effects of atypical antipsychotics, and this effect is likely to be related to its HSP co-inducing ability.",
keywords = "Atypical antipsychotic drugs, BGP-15, Diabetes, Heat-shock proteins, HSP, HSP inducers, HSP72, Hydroxylamines, Insulin resistance, Insulin signaling, Membranes, Metabolic syndrome, Mitochondria, Schizophrenia, Side effects, Therapy, Weight gain",
author = "Zsuzsanna Liter{\'a}ti-Nagy and K. Tory and Botond Liter{\'a}ti-Nagy and Attila Kolonics and Z. T{\"o}r{\"o}k and I. Gombos and G. Balogh and L{\'a}szl{\'o} V{\'i}gh and I. Horv{\'a}th and J. Mandl and B. S{\"u}megi and Hooper, {Philip L.} and L. V{\'i}gh",
year = "2012",
month = "7",
doi = "10.1007/s12192-012-0327-5",
language = "English",
volume = "17",
pages = "517--521",
journal = "Cell Stress and Chaperones",
issn = "1355-8145",
publisher = "Springer Netherlands",
number = "4",

}

TY - JOUR

T1 - The HSP co-inducer BGP-15 can prevent the metabolic side effects of the atypical antipsychotics

AU - Literáti-Nagy, Zsuzsanna

AU - Tory, K.

AU - Literáti-Nagy, Botond

AU - Kolonics, Attila

AU - Török, Z.

AU - Gombos, I.

AU - Balogh, G.

AU - Vígh, László

AU - Horváth, I.

AU - Mandl, J.

AU - Sümegi, B.

AU - Hooper, Philip L.

AU - Vígh, L.

PY - 2012/7

Y1 - 2012/7

N2 - Weight gain and dysfunction of glucose and lipid metabolism are well-known side effects of atypical antipsychotic drugs (AAPD). Here, we address the questionwhether a heat-shock protein (HSP) co-inducer, insulin sensitizer drug candidate, BGP-15, can prevent AAPD-induced glucose, lipid, and weight changes. We also examined how an AAPD alters HSP expression and whether BGP-15 alters that expression. Four different experiments are reported on the AAPD BGP-15 interventions in a human trial of healthy men, a rodent animal model, and an in vitro adipocyte cell culture system. Olanzapine caused rapid insulin resistance in healthy volunteers and was associated with decreased level of HSP72 in peripheral mononuclear blood cells. Both changes were restored by the administration of BGP-15. In Wistar rats, weight gain and insulin resistance induced by clozapine were abolished by BGP-15. In 3T3L1 adipocytes, clozapine increased intracellular fat accumulation, and BGP-15 inhibited this process. Taken together, our results indicate that BGP-15 inhibits multiple metabolic side effects of atypical antipsychotics, and this effect is likely to be related to its HSP co-inducing ability.

AB - Weight gain and dysfunction of glucose and lipid metabolism are well-known side effects of atypical antipsychotic drugs (AAPD). Here, we address the questionwhether a heat-shock protein (HSP) co-inducer, insulin sensitizer drug candidate, BGP-15, can prevent AAPD-induced glucose, lipid, and weight changes. We also examined how an AAPD alters HSP expression and whether BGP-15 alters that expression. Four different experiments are reported on the AAPD BGP-15 interventions in a human trial of healthy men, a rodent animal model, and an in vitro adipocyte cell culture system. Olanzapine caused rapid insulin resistance in healthy volunteers and was associated with decreased level of HSP72 in peripheral mononuclear blood cells. Both changes were restored by the administration of BGP-15. In Wistar rats, weight gain and insulin resistance induced by clozapine were abolished by BGP-15. In 3T3L1 adipocytes, clozapine increased intracellular fat accumulation, and BGP-15 inhibited this process. Taken together, our results indicate that BGP-15 inhibits multiple metabolic side effects of atypical antipsychotics, and this effect is likely to be related to its HSP co-inducing ability.

KW - Atypical antipsychotic drugs

KW - BGP-15

KW - Diabetes

KW - Heat-shock proteins

KW - HSP

KW - HSP inducers

KW - HSP72

KW - Hydroxylamines

KW - Insulin resistance

KW - Insulin signaling

KW - Membranes

KW - Metabolic syndrome

KW - Mitochondria

KW - Schizophrenia

KW - Side effects

KW - Therapy

KW - Weight gain

UR - http://www.scopus.com/inward/record.url?scp=84865114015&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865114015&partnerID=8YFLogxK

U2 - 10.1007/s12192-012-0327-5

DO - 10.1007/s12192-012-0327-5

M3 - Article

VL - 17

SP - 517

EP - 521

JO - Cell Stress and Chaperones

JF - Cell Stress and Chaperones

SN - 1355-8145

IS - 4

ER -